Introduction
============

Glutamate is the most important excitatory neurotransmitter in the central nervous system (CNS) ([@B223]). It is synthesized and stored in specific glutamatergic neurons until released into the synaptic cleft in response to specific stimuli. It then acts on glutamate receptors (including ionotropic and metabotropic receptors) on pre- and post-synaptic membranes and astrocytes to mediate signal transduction. It thereby plays a broad range of important roles in the brain, including roles in neuronal development ([@B133]), learning and memory ([@B47]; [@B143]), emotion ([@B189]; [@B183]) and neuroinflammation ([@B42]). Once in the synaptic cleft, glutamate is either re-taken up by the presynaptic membrane or promptly removed by astrocytes that are wrapped around the synapse ([@B163]). However, if excess extracellular glutamate is not cleared in a timely manner, glutamate receptors on the post-synaptic membrane will be excessively activated, resulting in excitotoxic injury, including the destruction of the Ca^2+^ buffer system ([@B199]), free radical-induced damage to mitochondria ([@B152]), and the inhibition of phosphatidylcholine-specific phospholipase C (PC-PLC) ([@B121]). Abnormally high levels of cytosolic Ca^2+^ and the massive release of inflammatory mediators in turn trigger the exocytosis-like release of glutamate from synaptic terminals, which results in the extracellular accumulation of glutamate and an amplifying cascade of excitatory toxicity that finally leads to the dysfunction and degeneration of neuronal synaptic transmission ([@B171]). The activation of ionotropic glutamate receptors can also produce neurotoxicity when uncoupled from neuroexcitation ([@B174]). Thus, the dramatic increase in intraparenchymal glutamate finally exacerbates the brain injury, leading to a poor prognosis ([@B173]).

Under normal conditions, blood glutamate levels are maintained in a steady state, and a normal diet prevents significant fluctuations in blood glutamate levels ([@B225]). In addition to the contributions of basic metabolic reactions, such as deamination and gluconeogenesis ([@B22]), it has more recently become clear that glutamate signaling has functions in non-neuronal tissues in sites as diverse as bone ([@B151]) and the pancreas ([@B140]), skin ([@B58]; [@B104]) and lungs ([@B41]) because the same vesicular release and receptor-mediated responses that have been documented at synapses in the CNS have been observed in these tissues. Moreover, researchers have also found that an excitotoxic reaction is induced by high levels of blood glutamate in these tissues that is similar to that induced in the CNS ([@B178]). In addition, our previous clinical results showed that high levels of blood glutamate are closely related to the occurrence of traumatic brain injury-induced acute lung injury (TBI-ALI) ([@B12]). These data further indicate that blood glutamate plays an important role in peripheral organs.

The intraparenchymal-blood glutamate concentration gradient is maintained in a relatively stable condition under physiological conditions ([@B78]). However, in a variety of brain diseases, the glutamate levels in the blood, cerebrospinal fluid (CSF) or both can significantly increase, and the normal intraparenchymal-blood glutamate concentration gradient is thereby disrupted (see **Table [1](#T1){ref-type="table"}**). These events have serious consequences for the brain ([@B184]; [@B217]) and peripheral tissues ([@B94]; [@B210]) and are associated with a worse prognosis ([@B51]). Here, we reviewed what is currently known about how the intraparenchymal-blood glutamate concentration gradient is maintained and regulated and investigated the potential clinical significance and impact of changes in this gradient on various brain insults.

###### 

Imbalanced intraparenchymal-blood glutamate concentration gradient in various brain insults.

  Brain insults            Research in humans/animals   Intraparenchymal glutamate   Blood glutamate   Reference
  ------------------------ ---------------------------- ---------------------------- ----------------- -----------------------------------
  **Acute brain injury**                                                                               
  SAH                      Humans/rats                  ↑                                              [@B145]; [@B14]
  AIS                      Humans/rats                  ↑                            ↑                 [@B200]; [@B28]; [@B20]
  TBI                      Humans/mice                  ↑                            ↑                 [@B208]; [@B118]; [@B41]; [@B12]
  ICH                      Rabbits                      ↑                                              [@B158]
  **Chronic disease**                                                                                  
  PD                       Humans                       ↑**/**↓                      N**/**↑           [@B92]; [@B132]
  AD                       Humans                       ↑**/↓**                      ↑                 [@B155]; [@B138]; [@B108]; [@B52]
  Epilepsy                 Humans/mice                  ↑**/↓**                                        [@B179]; [@B30]
  MS                       Humans                       ↑                            ↑                 [@B198]; [@B11]; [@B5]
  Schizophrenia            Humans                       ↓                            ↑                 [@B181]; [@B168]
                                                                                                       

AIS, acute ischaemic stroke; AD, Alzheimer's disease; ICH, intracerebral hemorrhage; MS, multiple sclerosis; PD, Parkinson's Disease; SAH, subarachnoid hemorrhage; TBI, traumatic brain injury.

The Formation and Maintenance of A Normal Intraparenchymal- Blood Glutamate Concentration Gradient
==================================================================================================

The glutamate concentration in the blood of healthy adults ranges from 40 to 60 μM ([@B12]). In some *in vitro* studies using acute brain slices, extracellular glutamate ranges from 25 to 90 nM ([@B29]; [@B80]; [@B110]); however, most *in vivo* studies using microdialysis, which is an FDA-approved method for clinical application, found much higher glutamate levels in brain, ranging from 0.2 μM to approximately 20 μM ([@B44]; [@B46]). Currently, researchers estimate a range from 1 to 10 μM in CSF or brain intercellular fluids ([@B74]; [@B119]; [@B194]). Under normal conditions, the glutamate concentration is many times higher in the blood than in the CSF, and the difference between the two is nearly 50 μM, thus giving rise to the intraparenchymal-blood glutamate concentration gradient ([@B74]). The maintenance of intraparenchymal glutamate homeostasis is largely dependent on the integrity of the blood--brain barrier (BBB) limiting the influx of blood glutamate and the activity of endothelial glutamate transporters (EAATs), which constantly transport intraparenchymal glutamate into the blood ([@B35]).

The Integrity of the BBB Is Required for a Normal Intraparenchymal-Blood Glutamate Concentration Gradient
---------------------------------------------------------------------------------------------------------

Glutamate is prevented from moving between the intraparenchymal and blood compartments by the BBB with intact integrity. The BBB is a physical barrier that protects the CNS from invasion by toxic substances in the blood. It has a high electrical impedance (≈2000 Ω/cm^2^), and restricts even the passage of ions ([@B39]; [@B176]). The BBB is composed of brain microvascular endothelial cells and junctional complexes, an endothelial basement membrane and the astrocyte end feet that surround the endothelial cells. Each layer of the BBB plays a role in restricting the flow of solutes ([@B1]; [@B192]).

Brain microvascular endothelial cells have more cytoplasmic vesicles and mitochondria than have been observed in the vessel endothelial cells of other tissues, in addition to more tight junctional complexes between cells ([@B148]; [@B106]). These junctional complexes include adhesion junctions and tight junctions (TJs). The former are composed of cadherin--catenin and related proteins, while TJs mainly consist of three types of integral membrane proteins, including Claudins ([@B122]), Occludins ([@B60]), and junctional adhesion molecules (JAMs) ([@B10]), in addition to a series of cytosolic accessory proteins, including members of the Zonula Occludens (ZO) family ([@B91]; [@B213]) and cingulin ([@B176]). These cytoplasmic proteins bind homotypically or assemble into heteropolymers, and they are responsible for the construction of the primary seal of TJs and essential for maintaining endothelial cell structure. In addition, the endothelial cell membrane is divided into the following two discrete parts by these TJs: the side facing the blood (called the luminal side) and the side facing the brain (called the abluminal side). Different populations of lipids and intrinsic proteins (e.g., glutamate transporters) reside in the luminal and abluminal spaces ([@B17]; [@B205]; [@B195]). The endothelial cells in the BBB are also surrounded by a continuous basement membrane that is mainly composed of collagen type IV, a variety of glycoproteins and pericytes. These proteins aggregate together to form a network that limits the flow of substances while simultaneously connecting with the surrounding tissue or extracellular matrix. They thereby play a supporting role in the BBB ([@B224]). Embedded pericytes act alone and in association with endothelial cells or astrocytes to play key roles in maintaining the structural stability of the vessel wall ([@B175]; [@B196]; [@B97]). Outside the basement membrane are enormous astrocyte end feet that surround approximately 85% of the surfaces of brain capillaries and play a role in regulating metabolism between brain vessels and neurons ([@B2]). Thus, the basement membrane and astrocytic end feet are together considered the "second barrier" between the blood and brain (as shown in **Figure [1](#F1){ref-type="fig"}**).

![Illustration of the components of the blood--brain barrier (BBB) and distribution of glutamate under normal and injury conditions. Under normal conditions, the structure of the BBB is intact and includes a bilayer of endothelial cells (including TJs), astrocyte end feet and pericytes in combination with a basement membrane. These layers separate glutamate into two relatively isolated circumstances: brain and blood. However, after a brain injury, the BBB is disrupted, and the levels of glutamate in blood and brain both markedly increase. This figure was modified from [@B125] with the permission of the authors. AFPs, astrocytic feet processes; BM, basement membrane; ECs, endothelial cells; EAATs, glutamate transporters; ISF, interstitial fluid; TJs, tight junctions.](fnmol-10-00400-g001){#F1}

Under physiological conditions, a high concentration of blood glutamate must cross at least five "films" (i.e., a bilayer of endothelial cells and astrocyte end feet in addition to the basement membrane) to enter the brain. In addition, a small amount of blood glutamate can be transported from the blood to the brain, and this process depends mainly on a Na^+^-independent carrier transporter (i.e., $X_{AG}^{-}/X_{G}^{-}$ transporters, which are mainly responsible for glutamate and aspartic acid) to be transported into endothelial cells, but this occurs at a low rate, and the carrier is close to saturation ([@B180]; [@B76]; [@B74]); additionally, a non-saturation transport that relies on the pores between endothelial cells may allow a very low rate of blood-brain flux of glutamate ([@B8]). Compared to other amino acids, glutamate is transported at a relatively low rate from the blood into the brain ([@B15]; [@B77]). Thus, only a very small amount of blood glutamate can normally cross the BBB into the brain ([@B105]; [@B31]) (see in **Figure [2](#F2){ref-type="fig"}**).

![Glutamate metabolism and transport between the intraparenchymal and blood environments. The concentration of glutamate in the brain ranges from 1 to 10 μM, which is much lower than that in blood (40--60 μM) and astrocytes and neurons (10--100 mM). Under normal conditions, intraparenchymal glutamate is mainly dependent on EAATs on astrocytes and the abluminal membrane of endothelial cells for transport into cells. When the glutamate concentration in an endothelial cell exceeds the blood concentration, glutamate will be transported into the blood via facilitative transport ($\mathit{X}_{AG}^{-}/\mathit{X}_{G}^{-}$); however, it is difficult for blood glutamate to enter the brain via either tight junctions or carriers. EAATs, glutamate transporters.](fnmol-10-00400-g002){#F2}

Na^+^-Dependent EAATs Are the Main Force Behind the Formation of a Normal Intraparenchymal-Blood Glutamate Concentration Gradient
---------------------------------------------------------------------------------------------------------------------------------

Despite the presence of physical barriers, however, the isolation of each compartment is not complete, and there is mutual flow between them. An active brain-to-blood efflux against the concentration gradient is thought to be the principal mechanism underlying this exchange ([@B147]; [@B76]; [@B78]), in which the Na^+^-dependent EAATs (hereafter referred to as EAATs) on endothelial cells are indispensable for the maintenance of the intraparenchymal-blood glutamate concentration gradient. EAATs are a family of high-homology transmembrane proteins that are composed of 500--600 amino acids and include EAAT~1~/GLAST, EAAT~2~/GLT-1, EAAT~3~/EAAC~1~, EAAT~4~, and EAAT~5~. They also share many similarities in their molecular structures, and they possess ([@B203]) 8 or 10 transmembrane segments, ([@B223]) a serine-rich motif located within the cytoplasmic or extracellular loop of the cytoplasmic or transmembrane region that contains common functional domains related to substrate-binding, ([@B133]) a glycosylation site in the second extracellular loop of each transporter, ([@B47]) the same PKA/PKC phosphorylation-regulating sites, ([@B143]) and a large hydrophobic region near the C-terminal that is different from that of other neurotransmitter transporters. These commonalities also determine their similar regulatory mechanisms ([@B98]; [@B99]). The expression of EAATs varies between different tissues. GLT-1 and GLAST are mainly expressed in glial cells, neurons and endothelial cells in brain, alone or in concert. EAAC~1~ is prevalent in the CNS (including the retina) and is mainly expressed in post-synaptic neurons ([@B63]; [@B56]). EAAT~4~ is highly enriched in Purkinje cells of the cerebellum ([@B134]), while EAAT~5~ is localized to two populations of glutamatergic neurons, bipolar neurons and photoreceptors in the retina ([@B111]). Thus, EAAT~1-3~ are the main transporters responsible for the vast majority of intraparenchymal glutamate transport in the brain. Many studies have demonstrated the necessity of EAAT~1-3~ in the maintenance and regulation of glutamate homeostasis under normal and pathological conditions (see in **Table [2](#T2){ref-type="table"}**).

###### 

Evidence for the necessity of EAAT~1-3~ in the maintenance and regulation of glutamate homeostasis.

  Research in normal/disease states   Intervention                Effects                                       Reference
  ----------------------------------- --------------------------- --------------------------------------------- -----------
  Normal                              Delta(9)-THC                ↓ GLAST/GLT-1, ↓ glutamate uptake             [@B27]
  Normal                              Ochratoxin A                ↓ GLAST/GLT-1, ↓ glutamate uptake             [@B159]
  Normal/hypoxic                      BDNF/CoCl~2~                ↑ GLAST, ↑ glutamate uptake                   [@B40]
  Alcohol consumption                 Per2 mutant                 ↓ GLAST, ↑ intraparenchymal glutamate         [@B182]
  Normal                              Antisense oligonucleotide   ↓ GLAST/GLT-1, ↑ intraparenchymal glutamate   [@B166]
  Hearing loss                        GLAST KO                    ↓ GLAST, ↑ intraparenchymal glutamate         [@B70]
  Normal                              Morphine                    ↓ EAAT3, ↑ extracellular glutamate            [@B68]
                                                                                                                

BDNF, brain-derived neurotrophic factor; KO, knock out.

Effective removal/uptake of excessive glutamate thus seems to be a crucial rescue mechanism, and failure or loss of the glutamate transport system may aggravate neurotoxic damage. In the CNS, a small proportion of the glutamate present in the synaptic cleft or intercellular fluid can undergo reuptake by the presynaptic membrane, but most of the extracellular glutamate is internalized into cells against a concentration gradient by EAATs located on glial cells or the endothelial cell membrane ([@B64]; [@B194]). One study has shown that when glutamate uptake is blocked, as little as 1 μM exogenous glutamate is sufficient to induce excitotoxic death in cortical neurons ([@B57]). Another study found that a 30-min exposure to 4 μM glutamate was sufficient to kill 50% of the neurons in astrocyte-poor cultures within 24 h, while 205 μM glutamate was required to kill the same percentage of neurons in astrocyte-rich cultures ([@B164]). While the importance of the brain for blood efflux was confirmed by microinjection of radiolabelled glutamate and the kinetics of its appearance in blood ([@B81]; [@B67]). In fact, glutamate uptake activity is so high that normal intact brain tissue is quite resistant to glutamate toxicity.

Endothelial glutamate transporters have a powerful scavenging ability that mainly depends on two processes: first and most important, EAATs are abundantly expressed on glial cells, especially astrocytes ([@B167]; [@B9]); additionally, astrocytes are rich in glutamine synthetase, which transforms extracellular glutamate into glutamine that can be pumped into cells to sustainably maintain a low concentration outside the cell ([@B43]). Thus, EAATs play a major role in the clearance of intraparenchymal glutamate ([@B219]). Second, although the expression of EAATs is greatly reduced on endothelial cells ([@B114]), the brain is a highly vascularized organ \[human brain contains approximately 100 million capillaries and a surface area of approximately 12 m^2^ ([@B19])\]. In addition, almost every neuron in the brain has an adjacent capillary, and the average distance between a capillary and a neuron is only 8--20 μm ([@B172]). Therefore, EAAT-rich cerebral vessels and perivascular astrocyte end feet are particularly important for the formation and maintenance of intraparenchymal glutamate homeostasis. The driving force exerted by EAATs against the glutamate concentration gradient involves secondary active transport coupled to Na^+^, K^+^-ATPase (NKA). Intracellular Na^+^ is pumped out of the cell, while K^+^ is pumped into the cell, causing a Na^+^ concentration gradient from the extracellular to the intracellular compartment. EAATs cotransport one glutamate and three Na^+^ \[or two Na^+^ and one H^+^ ([@B144])\] into the cell. Assuming that the empty transporter is electrically neutral, the static charge of a full transport is one or two, and transport therefore generates electricity ([@B99]).

Astrocytic and endothelial EAATs both play a crucial role in the regulation of intraparenchymal glutamate; however, endothelial EAATs play an important and unique function in the homeostasis of the intraparenchymal-blood glutamate concentration gradient since they lie directly between the brain and blood. A large number of studies have shown that endothelial EAATs are present only on the abluminal membrane ([@B147]; [@B79]). Under normal circumstances, the level of intraparenchymal glutamate depends on EAATs located on the endothelial abluminal membrane that transport it from the intraparenchymal space to the blood. At present, a widely accepted and confirmed view is that extracellular glutamate in the brain is continuously transported into microvascular endothelial cells, which become enriched, by abluminal EAATs against a glutamate concentration gradient. When the glutamate concentration in an endothelial cell exceeds the blood concentration, glutamate will be transported into the blood via facilitative transport ([@B147]; [@B76]). This process is also called "concentration climbing" and is considered the most important mechanism for forming and maintaining the intraparenchymal-blood glutamate concentration gradient under physiological conditions ([@B79]). Previously, one plausible mechanism was proposed that glutamate efflux from brain extracellular fluids into the blood might involve a "glutamine-glutamate cycle" ([@B116]; [@B147]). In such a mechanism, the uptake of excess glutamate into astrocytes leads to its conversion into glutamine, which is released by astrocyte end feet and is subsequently pumped into endothelial cells via glutamine transporters and then converted back into glutamate. However, the results of further experiments using an isolated BBB model quickly eliminated the hypothesis that a "glutamate--glutamine" cycle makes no contribution to brain endothelial cell uptake of intercellular glutamate ([@B35]). In addition to this process, the glutamate in intercellular fluids can first be taken up into astrocyte end feet and then excreted via exocytosis ([@B212]; [@B38]) and volume-regulated anion channels (VRAC) ([@B193]) and hemichannels ([@B218]) before being transported into endothelial cells by glutamate transporters (as shown in **Figure [2](#F2){ref-type="fig"}**).

The Contribution of the Glymphatic System to the Formation of a Normal Intraparenchymal-Blood Glutamate Concentration Gradient
------------------------------------------------------------------------------------------------------------------------------

A long-held anatomical view states that the brain lacks a lymphatic system but instead uses CSF reflux. However, recent studies have suggested that in addition to endothelial cells, a novel pathway operates at the blood--brain interface, which may involve a separate paravascular highway that facilitates the rapid exchange of CSF and tissue fluids. This pathway has been referred to as the "glymphatic system" ([@B87]). The glymphatic system (or glymphatic clearance pathway) is a functional waste clearance pathway in the vertebrate CNS. The pathway consists of a para-arterial influx route by which CSF enters the brain parenchyma coupled to a clearance mechanism by which interstitial fluid (ISF) and extracellular solutes are removed from the interstitial compartments of the brain and spinal cord. The exchange of solutes between the CSF and the ISF is driven by arterial pulsation ([@B89]) and regulated during sleep by the expansion and contraction of the brain extracellular space ([@B136]). The clearance of soluble proteins \[such as beta amyloid (Abeta), phosphorylated tau (p-tau) and Apolipoprotein E (apoE)\] ([@B88]; [@B4]; [@B186]), waste products (such as lactate) ([@B128]), and excess extracellular fluid (which contain small-molecule intraparenchymal glutamate and other brain injury markers) ([@B216]; [@B197]; [@B154]) is accomplished via the convective bulk flow of the ISF and facilitated by astrocytic aquaporin 4 (AQP4) water channels (see in **Figures [1](#F1){ref-type="fig"}**, **[2](#F2){ref-type="fig"}**).

The Intraparenchymal-Blood Glutamate Concentration Gradient Is Imbalanced Under Pathological Conditions
=======================================================================================================

Despite controversy, most studies have found that when various types of acute brain injury, such as subarachnoid hemorrhage (SAH), acute ischaemic stroke (AIS), intracerebral hemorrhage (ICH), or TBI occurs, glutamate levels in the brain and blood can reach extremely high levels. This elevation has also been observed in patients with chronic brain diseases, such as Parkinson's Disease (PD), Alzheimer's disease (AD), epilepsy, multiple sclerosis (MS) and schizophrenia (see in **Table [1](#T1){ref-type="table"}**). Glutamate levels in the blood and CSF are significantly higher in patients with these conditions than in normal individuals, and the intraparenchymal-blood glutamate concentration gradient is also dramatically increased.

Sources of Elevated Intraparenchymal Glutamate
----------------------------------------------

A tremendous amount of glutamate is stored in brain neurons and glial cells at a concentration of up to 10--100 mM ([@B129]; [@B135]). Previous studies have shown that when a brain injury occurs, in addition to the direct destruction of neurons and glial cells, a massive amount of glutamate is released into the brain intercellular fluid by other mechanisms ([@B101]). These include external Ca^2+^- or intracellular Ca^2+^-dependent vesicular release ([@B50]; [@B102]), release via swelling-activated anion channels ([@B13]), an indomethacin-sensitive process in astrocytes ([@B150]; [@B73]; [@B18]), and glutamate transporter dysfunction ([@B191]; [@B190]). By using blockers that affect each release mechanism, researchers have demonstrated that glutamate release is largely caused by the dysfunction of glutamate transporters ([@B165]). Conversely, this is due in part to a reduction in the expression of these transporters. For example, in patients with TBI, researchers found that reduced survival and degeneration in astrocytes resulted in a significant decrease in the expression of EAAT~1/2~ within 7 days after injury ([@B204]; [@B16]), and shear or inertial force also caused changes in EAAT expression and activity-associated astrocyte deformation in TBI ([@B202]). In contrast, in such cases, the dysfunction of EAATs manifested as decreased activity and reduced transport efficiency, but reverse transport remained possible. In acute ischaemia in the hippocampus, reversed transport of neuronal EAATs resulted in a sharp increase in extracellular glutamate levels ([@B165]). Moreover, under inflammatory conditions, which consistently accompany brain insults, the release of pro-inflammatory cytokines not only inhibited glutamate scavenging capacity ([@B55]) but also reduced EAAT~2~ expression in astrocytes ([@B169]; [@B177]).

Previously, there has been widespread controversy regarding whether the BBB is severely physically destroyed following brain injury. Although some reports have suggested that the structure of the BBB after brain injury becomes damaged and loses part of its barrier function ([@B206]; [@B209]), most studies nevertheless suggest that the direct damage (i.e., vascular rupture caused by brain contusion) is limited ([@B221]), but that its functional components (i.e., junctional complexes between endothelial cells) might suffer more severe damage ([@B221]; [@B156]), which could last for a long time ([@B95]). Under pathological conditions, such as shock or inflammation or the presence of a tumor, the expression of Claudin-1 and Occludin dramatically decrease in blood vessels ([@B123]; [@B149]). Experiments in which dye was injected into animals ([@B3]; [@B84]) or magnetic resonance imaging (MRI) in humans ([@B137]) confirmed the increased permeability of the BBB after a brain injury. The results of these studies suggest that increased blood glutamate can also penetrate into the brain via the functionally impaired BBB and play specific roles in the increased intraparenchymal glutamate observed after brain injury (shown in **Figure [1](#F1){ref-type="fig"}**).

The transport of intraparenchymal glutamate by the glymphatic system can also be decreased. In a variety of animal models of brain insult, including models of AD ([@B215]), aging ([@B107]), epilepsy ([@B83]), and ICH ([@B157]), AQP4 expression is decreased and its polarity is impaired. The outflow of CSF was significantly lower in AQP4 knockout (KO) mice than in wild type mice, and the clearance rate of intercellular fluid was also greatly reduced ([@B154]). However, while the decrease in its expression had largely normalized by 7 days post-injury, AQP4 depolarization continued to be observed ([@B222]). Moreover, a separate study also found that AQP4 is co-expressed with GLT-1 on brain perivascular astrocytes, whereas genetically knocking out AQP4 inhibited the expression of GLAST, resulting in the inhibition of intraparenchymal glutamate efflux ([@B120]).

Sources of Elevated Blood Glutamate
-----------------------------------

The sources of the observed elevation in blood glutamate levels have remained unclear. Researchers have analyzed the rate of glutamate uptake in various peripheral tissues and organs after intravascular injection of \[^14^C\]-Glu and found that skeletal muscle contain the body's largest storage pool of glutamate, accounting for approximately 59% of the total storage amount ([@B105]). In patients with acute spinal cord injury (SCI), researchers have found that an ion distribution disorder caused by the abnormal expression of NKA and its FXYD1 subunit in skeletal muscle may be the molecular basis underlying the release of glutamate from skeletal muscle after injury ([@B21]). Blood cells are another important source of blood glutamate. A comparison of patients with cerebral infarction and healthy controls has revealed that the glutamate-releasing ability of platelets is reduced in patients, suggesting that at the onset of a brain infarct, platelets are activated, which frees up a large amount of glutamate to enter the blood ([@B7]; [@B141]). Additionally, *in vitro* experiments have shown that the endothelial barrier function is altered by the release of soluble polymorphonuclear leukocyte (PMN)-derived glutamate during inflammatory states ([@B36]). In addition, bone might be another source of glutamate because osteoclasts also secrete [L]{.smallcaps}-glutamate in a Ca^2+^-dependent manner when stimulated with KCl or ATP ([@B139]).

The Regulatory Mechanisms Underlying the Imbalance in the Glutamate Concentration Gradient
==========================================================================================

The key processes goals when resolving imbalances in intraparenchymal-blood glutamate homeostasis are to reduce the elevated glutamate levels in both the blood and the brain, which includes preventing the entry of blood glutamate into the brain and enhancing the transport efficiency of glial and endothelial EAATs and the glymphatic system under pathological conditions. Thus, based on the previously discussed mechanism underlying the formation of the intraparenchymal-blood glutamate concentration gradient, we now review the regulatory mechanisms involved in modulating EAATs, TJs, the glymphatic system and glutamate itself.

Regulatory Mechanisms That Affect EAATs Expression and Function
---------------------------------------------------------------

Many factors were involved in the mRNA or protein turnover of EAATs to regulate their expression and distribution. Both glutamate and kainite dramatically increase GLAST protein expression in cultured astrocytes without significantly increasing the amount of GLAST mRNA ([@B62]). [L]{.smallcaps}-DOPA and ceftriaxone both increase GLT-1 expression, but they exert opposite effects on the intraparenchymal glutamate ([@B160]; [@B115]). Studies have suggested that proteins translated from aberrant mRNAs may undergo rapid degradation and/or produce a dominant-negative effect on normal EAAT~2~ proteins that reduces the amount of the protein and its activity ([@B124]). Hence, while a glutamate transporter and the expression of its corresponding mRNA can differ according to the cell phenotype, cellular environment and locally active signaling pathways, the specific mechanism underlying these differences is unknown ([@B63]). Studies examining these differences at the post-translational level have primarily focused on modifications of EAATs, including their phosphorylation, glycosylation, and ubiquitination. Previous experiments have confirmed that the expression and uptake efficiency of EAATs are dependent on a PKA/PKC pathway ([@B26]; [@B54]; [@B82]), and amelioration of the delayed ischaemic brain damage can be achieved by increasing both the expression and function of EAAT~1~ via these pathways ([@B214]; [@B100]). The effect of glycosylation on EAATs remains controversial. Observations of the *N*-glycosylation of GLAST demonstrated that the kinetic characteristics of GLAST are not affected ([@B37]), while another study of EAAC~1~ found that glycosylation may be necessary for the activity of the transporter under hypertonic stress ([@B53]). However, no clear mechanism has been identified to explain how this glycosylation is regulated. Recent evidence indicates that the turnover of EAATs in the plasma membrane is accelerated by an ubiquitin-dependent process, which is triggered by the activation of PKC ([@B66]; [@B61]). Amphetamine triggers the internalization of EAAT~3~ but simultaneously produces a dose-related increase in extracellular concentrations of glutamate ([@B49]; [@B201]) (see also **Table [3](#T3){ref-type="table"}**).

###### 

Factors involved in the regulation of EAATs and TJs.

  Factors involved        *In vivo*/*In vitro* studies   Effects                                                     Reference
  ----------------------- ------------------------------ ----------------------------------------------------------- ------------------
  **EAATs**                                                                                                          
  Glutamate and kainite   *In vitro*                     ↑ GLAST protein expression without mRNA change              [@B62]
  [L]{.smallcaps}-DOPA    *In vivo*                      ↑ GLT-1expression                                           [@B160]
  Ceftriaxone             *In vitro*                     ↑ EAAT~2~ expression                                        [@B115]
  Arundic acid            *In vivo*/*In vitro*           ↑ EAAT~1~ expression ↑ EAAT~1~ activity (phosphorylation)   [@B214]; [@B100]
  Hypertonic stress       *In vitro*                     ↑ EAAC~1~ activity (glycosylation)                          [@B53]
  Amphetamine             *In vitro*                     ↑ EAAT~3~ endocytosis                                       [@B201]
  **TJs**                                                                                                            
  Ca^2+^                  *In vitro*                     ↑ migration of ZO-1                                         [@B185]
  Insulin                 *In vivo*/*In vitro*           ↑ TJs integrity                                             [@B188]; [@B90]
  Dexmedetomidine         *In vivo*/*In vitro*           ↑ ZO-1 and Occludin expression                              [@B85]; [@B126]
  IFN-γ                   *In vivo*/*In vitro*           ↓ TJs protein expression                                    [@B32]; [@B71]
  Glutamate               *In vivo*                      ↑ BBB permeability                                          [@B207]
  A~2A~R                  *In vivo*                      ↓ TJs protein expression                                    [@B119]; [@B25]
                                                                                                                     

A

2A

R, adenosine 2A receptor; EAATs, glutamate transporters;

L

-DOPA, 3-(3,4-Dihydroxyphenyl)-

L

-alanine; TJs, tight junctions.

Because glutamate transport is associated with ion transport, the regulation of ions may significantly impact the function of transporters. In shock or TBI cases, ischaemia and hypoxia lead to a deficiency in energy synthesis, and ATP deficiency-induced mitochondrial dysfunction directly affects Na^+^-K^+^ pumps and Na^+^-Ca^2+^ and Na^+^-H^+^ exchange, resulting in a disordered charge distribution both in and outside the cell membrane. The transfer efficiency is then decreased, and in some cases, uncontrolled reverse transport occurs, resulting in the release of glutamate. Hence, these processes can eventually result in high concentrations of extracellular glutamate ([@B191]; [@B165]; [@B220]). When the intracellular Na^+^ concentration increases from 15 to 30 mM, glutamate transporters began to reverse transport. However, when a Na^+^-H^+^ antiporter inhibitor was applied, it induced rapid extensive intracellular acidosis and glutamate transporter reversal but not an overload of intracellular Na^+^. H^+^ may therefore play an equally important role in regulating the direction in which EAAT is transported with Na^+^ ([@B65]; [@B127]). Although the number of studies examining glutamate transporters has gradually increased, the precise mechanisms by which Na^+^, K^+^, and H^+^ lead to reverse transport remain unresolved and require further investigation ([@B131]). In addition to these mechanisms, there may also be other routes by which extracellular glutamate concentrations can be quickly altered, including the regulation of EAAT activity, and this topic is worthy of further exploration.

Pathways Involved in the Regulation of Endothelial TJ Expression
----------------------------------------------------------------

Many signaling pathways and endo/exogenous factors have been shown to regulate the assembly of TJs ([@B93]). Abnormalities in Ca^2+^ homeostasis have been implicated in the pathophysiology of brain injury ([@B187]), and one reason for this phenomenon is that Ca^2+^ is tightly connected to the regulation of TJs both in and outside the cell ([@B109]). Changes in intracellular Ca^2+^ levels can trigger a series of PKA- or PKC-mediated molecular events that increase transendothelial resistance and promote the migration of ZO-1 from the cytoplasm to the membrane ([@B185]). Brain injury is consistently accompanied by alterations in hormones, such as insulin ([@B96]) and cortisol ([@B6]), which also play an important role in the regulation of TJs. In both an *in vitro* model of BBB and *in vivo* research, insulin and dexamethasone were found to rapidly increase the expression of TJs and decrease permeability ([@B85]; [@B126]; [@B188]; [@B90]). Researchers observed a significant decrease in blood glutamate after injection of insulin ([@B228]); however, there was no significant correlation between blood glutamate levels and brain uptake of glutamate ([@B75]); in contrast, dexamethasone greatly augmented the intraparenchymal glutamate level after ischaemia ([@B33]). Blocking some chemokines/cytokines, such as IFN-γ, ameliorates both the disruption of BBB permeability and the down-regulation of TJ protein expression ([@B32]), and an increase in cortex glutamate has been observed after treatment with IFN-γ ([@B71]). Intraparenchymal glutamate itself also induces changes in BBB permeability ([@B207]). Additionally, the rapidly increased adenosine acting on the adenosine 2A receptor (A~2A~R) after a brain injury can cause cytoskeletal changes in endothelial cells while simultaneously reducing the expression of TJs, thereby increasing BBB permeability ([@B34]; [@B25]). Furthermore, the elevated intraparenchymal glutamate level is counteracted by A~2A~R inactivation ([@B119]) (see also **Table [3](#T3){ref-type="table"}**).

The Function of the Glymphatic System Is Closely Related to AQP4
----------------------------------------------------------------

The results of several studies have confirmed that astrocytic AQP4 plays an importantly role in clearance in the glymphatic system ([@B89], [@B86]; [@B142]). As previously stated, anatomical associations have supported the notion of an interaction between endothelial cells and astrocytes ([@B2]). Research has shown that endothelial cells promote the accumulation of AQP4 by exerting an inductive effect on extracellular matrix components such as agrin and via direct mechanical interactions with end foot processes ([@B23]). Using an *in vitro* model of BBB, the results of another study confirmed that both the amount and localization of AQP4 protein in astrocytes were influenced by direct contact with endothelial cells ([@B72]). In addition, the expression of AQP4 is influenced by other factors. Progesterone significantly reduced AQP4 expression in peri-contusion areas ([@B69]), the activation of P2X7R in astrocytes was associated with the down-regulation of AQP4 in rat brain astrocytes ([@B113]), and in our previous experiments, we found that AQP4 expression was significantly lower in the brain cortex in A~2A~R KO mice than in wild type controls following brain blast injury, suggesting that A~2A~R activity may affect the expression of AQP4 ([@B146]).

Pathways and Regulation of Glutamate Itself
-------------------------------------------

Many enzymes or substrates are directly involved in the metabolic process of glutamate. Glutamate dehydrogenase (GDH) is important in the transdeamination of glutamate, as activation of GDH not only significantly decreases the glutamate concentration in brain ([@B112]) but also restores alpha-ketoglutarate (alpha-KG) and ATP levels after brain ischaemia ([@B103]) and increases glutamate uptake in the forebrain ([@B211]). Glutamine synthetase (GS) plays a key role in intraparenchymal glutamate metabolism, as after ischaemia, an increase in GS in astrocytes occurs rapidly and in parallel with proliferative changes in astrocyte organelles ([@B153]). In blood, the substrates of glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT), oxaloacetate and pyruvate have also demonstrated powerful scavenging capacity ([@B229]).

The Interrelationship Between Intraparenchymal and Blood Glutamate
==================================================================

As previously mentioned, glutamate does not exist in isolation in the brain or blood. In one study, as the glutamate concentration rose from 1 to 500 μM in the carotid artery in primary hypertension rats, the rate at which glutamate penetrated the brain increased ([@B8]); additionally, systemic injection of glutamate has been reported to aggravate brain damage ([@B229]). Another study showed that intravenous administration of aspartate aminotransferase (AST) ([@B170]), pyruvate and oxaloacetate ([@B226], [@B229]) could significantly reduce glutamate levels in the blood in addition to accelerating the discharge of glutamate from the brain, decreasing intraparenchymal glutamate levels ([@B194]), significantly improving prognoses and outcomes ([@B24]), and extending the lifetimes of the mice ([@B227], [@B226]; [@B105]). These findings indicate that the environments in the brain and blood are mutually influenced, and blood glutamate is of great significance for the brain. However, the effect of elevated blood glutamate on the concentration of intraparenchymal glutamate and whether it is also an important source of the rapid increase in intraparenchymal glutamate remain poorly understood. Moreover, while there is no direct evidence showing that intraparenchymal glutamate levels influence blood glutamate levels, the results of our recent studies in patients with TBI indicate that the severity of brain injury is positively associated with blood glutamate levels ([@B12]).

The Significance of Potential Applications That Alter the Homeostasis of the Intraparenchymal-Blood Glutamate Concentration Gradient
====================================================================================================================================

In an effort to ensure that "CNS security" is made an appropriate priority in pathological cases, administering a glutamate receptor antagonist following a brain insult has, in many pre-clinical studies, indicated neuro-protective roles and improved prognoses ([@B59]; [@B48]). However, the results of clinical trials have suggested that these drugs fail to improve long-term prognoses or reduce mortality after brain injury ([@B45]; [@B117]; [@B130]). We hypothesized that this might be because the important role of blood glutamate (and therefore the intraparenchymal-blood glutamate concentration gradient) was ignored. Because haemofiltration ([@B161]) and peritoneal dialysis ([@B162]) have been approved to efficiently lower blood glutamate levels in patients, these measures could be used to treat acute and chronic brain disorders that are accompanied by elevated glutamate levels in both the brain and blood.

However, many unsolved issues remain. For example, is peripheral glutamate an important source of increased intraparenchymal glutamate following a brain injury? Can blood glutamate act as a diagnostic or prognostic indicator of brain injury? Only by increasing our understanding of the generation and metabolism of intraparenchymal-blood glutamate can we identify methods to regulate the glutamate concentration gradient at the source and thereby prevent the damaging effects of high levels of glutamate. Such studies would offer important and effective methods for treating the acute phase of brain injury.
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